Virtual seminar on March 27 – 29, 2023

DiaSys has been taking up virtual seminars more frequently. This time, Marketing and Sales have been pleased to welcome approx. 20 participants from the lately appointed distributors Sysmex Co., Republic of South Africa, and from Amilab, Chile, South America. Three sessions of approximately two hours each on three consecutive days offered the opportunity to get an idea of DiaSys’ broad portfolio but especially of some “eye-catching” dedicated, extraordinary parameters. Mr. Christophe Bayet, Head of Global Sales welcomed the participants together with Mr. David Ehlers, Strategic Product Manager Systems, who provided more detailed company facts, and was moderating the event. He well introduced HbA1c in the context of diabetes management, and presented DiaSys’ concept of calibrators and controls, perfectly matched to reagents, and pointed at the importance of quality control in the lab.

Mr. Malte Hilsch, Strategic Product Manager Reagents convinced attendees that quality and excellent performance is DiaSys’ priority and introduced the enhanced products for lipid diagnostics HDL-c direct FS and LDL-c direct FS. In further presentations, he demonstrated why D Dimer is vital in thromboembolic events, and outlined DiaSys parameters for renal diagnostics.

The clinical utility of the liver function panel was illustrated by Dr. Adelina Jashari, Strategic Product Manager Reagents, who put a strong focus on the bilirubin metabolism.

Péter Aradi, Area Business Director highlighted Procalcitonin FS, known as a cost-efficient, precise and timesaving parameter for reliable quantitative in vitro determination of sepsis, a leading cause of death in hospitals. Péter talked about the outstanding reagent CRP FS for detection of inflammation and shared his wide experience in the sales market.

The seminar offered good ground for participants to get to know each other, give feedback from the market, and update knowledge. Further communication will surely follow on a colleague-to-colleague basis; a first follow-up visit in Germany has already been announced. We are looking forward to cooperating with our new partners.